Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
US drugmaker Vertex Pharmaceutical (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and, in particular, its Alyftrek (vanzacaftor/tezacaftor/deutivacaftor). 7 June 2025
Related News
Insights
Company Spotlight
A California-based biotech company aiming to deliver a new class of RNA therapeutics.
Latest News & Features of interest to Vertex Pharmaceuticals
Biotechnology
US biotech PureTech Health is positioning its lead candidate LYT-100 as a potential disruptor in the treatment of idiopathic pulmonary fibrosis (IPF), a rare lung condition long underserved by current therapies. 9 June 2025
Biotechnology
Regulatory news last week included US biotech Moderna receiving Food and Drug Administration (FDA) approval for its new COVID-19 Vaccine mNEXSPIKE. On the M&A front, French pharma major Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology pipeline. USA-based Cullinan Therapeutics has entered into a license deal with China's Genrix Bio for the latter’s velinotamig for multiple myeloma. Also of note, RegeNXBio released what lookedlike good results for its investigational Duchenne muscular dystrophy drug RGX-202. 8 June 2025
Pharmaceutical
US drugmaker Vertex Pharmaceutical (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and, in particular, its Alyftrek (vanzacaftor/tezacaftor/deutivacaftor). 7 June 2025
Biotechnology
Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III VALIANT study, investigating Aspaveli/Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). 6 June 2025
Biotechnology
Japan’s Otsuka today presented positive results from a pre-specified interim analysis of the Phase III VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. 6 June 2025
Biotechnology
The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the development of new drug therapy options to treat this disease, according to a report from DelveInsight. 6 June 2025
Pharmaceutical
US biotech Trevi Therapeutics has raised around $115 million in a public stock offering, giving it fresh momentum to continue developing its investigational therapy Haduvio (nalbuphine) for chronic cough. 6 June 2025
Biotechnology
US gene therapy company RegeNXBio yesterday announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates include positive functional, safety and biomarker data for RGX-202, RegeNXBio’s potential best-in-class, investigational gene therapy for Duchenne muscular dystrophy. 6 June 2025
Biotechnology
The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal cell carcinoma patients who have failed prior treatment with one tyrosine kinase inhibitor (TKI) has been accepted for review by the China National Medical Products Administration (NMPA). 5 June 2025
Biotechnology
US rare disease meds developer Sarepta Therapeutics revealed that its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the US Food and Drug Administration. 5 June 2025
Latest In Brief for Vertex Pharmaceuticals
Biosimilars
At its May meeting, the European Medicines Agency’s (EMA) human medicines committee (CHMP) adopted positive opinions for three biosimilar medicines: 23 May 2025
Latest Relevant Ones To Watch News
Regulatory news last week included US biotech Moderna receiving Food and Drug Administration (FDA) approval for its new COVID-19 Vaccine mNEXSPIKE. On the M&A front, French pharma major Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology pipeline. USA-based Cullinan Therapeutics has entered into a license deal with China's Genrix Bio for the latter’s velinotamig for multiple myeloma. Also of note, RegeNXBio released what lookedlike good results for its investigational Duchenne muscular dystrophy drug RGX-202. 8 June 2025
16 May 2025
30 April 2025
28 April 2025
24 March 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze